List of bibliographic references
Number of relevant bibliographic references: 4.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Humans (MeSH) |
| 3 | Betacoronavirus (MeSH) |
| 3 | Pandemics (MeSH) |
| 2 | Antiviral Agents (therapeutic use) |
| 2 | Chlorpromazine (therapeutic use) |
| 2 | Coronavirus Infections (drug therapy) |
| 2 | Coronavirus Infections (epidemiology) |
| 2 | Drug Repositioning (MeSH) |
| 2 | Endocytosis (drug effects) |
| 2 | France (MeSH) |
| 2 | France (epidemiology) |
| 2 | Patient Selection (MeSH) |
| 2 | Pilot Projects (MeSH) |
| 2 | Pneumonia, Viral (drug therapy) |
| 2 | Pneumonia, Viral (epidemiology) |
| 2 | Procedures and Techniques Utilization (MeSH) |
| 2 | Single-Blind Method (MeSH) |
| 1 | Antiviral Agents (pharmacokinetics) |
| 1 | Antiviral Agents (pharmacology) |
| 1 | Anxiety (complications) |
| 1 | Anxiety (drug therapy) |
| 1 | Anxiety (epidemiology) |
| 1 | Anxiety (pathology) |
| 1 | Betacoronavirus (pathogenicity) |
| 1 | Biomarkers (MeSH) |
| 1 | Bipolar Disorder (therapy) |
| 1 | Blood-Brain Barrier (MeSH) |
| 1 | Blood-Brain Barrier (drug effects) |
| 1 | Chlorpromazine (pharmacokinetics) |
| 1 | Chlorpromazine (pharmacology) |
| 1 | Clathrin-Coated Vesicles (drug effects) |
| 1 | Clinical Trials, Phase III as Topic (methods) |
| 1 | Communicable Disease Control (MeSH) |
| 1 | Communicable Disease Control (legislation & jurisprudence) |
| 1 | Communicable Disease Control (methods) |
| 1 | Continuity of Patient Care (MeSH) |
| 1 | Coronavirus Infections (MeSH) |
| 1 | Coronavirus Infections (complications) |
| 1 | Coronavirus Infections (immunology) |
| 1 | Coronavirus Infections (pathology) |
| 1 | Coronavirus Infections (prevention & control) |
| 1 | Coronavirus Infections (transmission) |
| 1 | Cytokines (blood) |
| 1 | Delivery of Health Care (MeSH) |
| 1 | Depressive Disorder (therapy) |
| 1 | Disease Progression (MeSH) |
| 1 | Dose-Response Relationship, Drug (MeSH) |
| 1 | Dyspnea (drug therapy) |
| 1 | Dyspnea (epidemiology) |
| 1 | Dyspnea (pathology) |
| 1 | Dyspnea (psychology) |
| 1 | Electroconvulsive Therapy (methods) |
| 1 | Electroconvulsive Therapy (standards) |
| 1 | Electroconvulsive Therapy (statistics & numerical data) |
| 1 | Electroconvulsive Therapy (trends) |
| 1 | Hospitals, Private (MeSH) |
| 1 | Hospitals, Psychiatric (organization & administration) |
| 1 | Hospitals, Public (MeSH) |
| 1 | Length of Stay (MeSH) |
| 1 | Lung (metabolism) |
| 1 | Mental Disorders (drug therapy) |
| 1 | Mental Disorders (epidemiology) |
| 1 | Mortality (MeSH) |
| 1 | Multicenter Studies as Topic (methods) |
| 1 | Nursing Homes (MeSH) |
| 1 | Pandemics (prevention & control) |
| 1 | Patient Outcome Assessment (MeSH) |
| 1 | Patient Safety (MeSH) |
| 1 | Pneumonia, Viral (MeSH) |
| 1 | Pneumonia, Viral (complications) |
| 1 | Pneumonia, Viral (immunology) |
| 1 | Pneumonia, Viral (pathology) |
| 1 | Pneumonia, Viral (prevention & control) |
| 1 | Pneumonia, Viral (transmission) |
| 1 | Practice Guidelines as Topic (MeSH) |
| 1 | Protective Devices (MeSH) |
| 1 | Randomized Controlled Trials as Topic (methods) |
| 1 | Recovery of Function (MeSH) |
| 1 | Research Design (MeSH) |
| 1 | Saliva (metabolism) |
| 1 | Severity of Illness Index (MeSH) |
| 1 | Social Isolation (MeSH) |
| 1 | Time-to-Treatment (MeSH) |
| 1 | Tissue Distribution (MeSH) |
| 1 | Treatment Outcome (MeSH) |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "M. Plaze"
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i \
-Sk "M. Plaze" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= France
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= M. Plaze
}}
| This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021 |  |
